Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Triple Negative Breast Neoplasms 1Solid Tumor 1Prostatic Neoplasms, Castration-Resistant 1Pancreatic Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

enzalutamide 5Docetaxel 3zimberelimab 1sacituzumab govitecan 1quemliclustat 1olaparib 1gedatolisib 1fludrocortisone acetate 1darolutamide 1cabazitaxel 1abiraterone 1Prednisone 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Prostatic Neoplasms, Castration-Resistant × zimberelimab × Clear all
NCT04381832 2025-07-22

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Arcus Biosciences, Inc.

Phase 1/2 Completed
173 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡